Isofluran Baxter

Isoflurane, the active ingredient in Isofluran Baxter, is a volatile anesthetic presented as a liquid for inhalation use. It produces rapid loss of consciousness and analgesia, making it suitable for induction and maintenance of general anesthesia in adult and pediatric surgical patients.

GNH USA supplies Isofluran Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics and responsive technical support.

Isoflurane is a volatile anesthetic used in the central nervous system to produce reversible loss of consciousness.

- Induction of general anesthesia: rapid onset of unconsciousness for surgical procedures - Maintenance of general anesthesia: sustained anesthetic depth throughout operations - Procedural sedation: provides deep sedation for short diagnostic or therapeutic procedures

Isoflurane may cause a range of adverse reactions during and after administration.

Common Side Effects: - Airway irritation: cough or laryngospasm - Hypotension: decreased blood pressure - Respiratory depression: reduced ventilation - Nausea: mild postoperative nausea

Serious or Rare Side Effects: - Malignant hyperthermia: rare life‑threatening hypermetabolic reaction - Hepatotoxicity: rare elevation of liver enzymes - Cardiac arrhythmia: occasional abnormal heart rhythms

Isoflurane requires careful patient assessment and monitoring before and during use.

- Patient monitoring: continuous cardiovascular and respiratory monitoring required - Pre‑existing liver disease: use with caution - Pregnancy: safety not established, avoid if possible - Concurrent CNS depressants: may potentiate respiratory depression - Malignant hyperthermia susceptibility: contraindicated - Store at ambient temperature: keep container sealed, protect from light and moisture

Isoflurane can interact with other agents, altering its anesthetic profile.

Major Interactions (Avoid): - Potent CYP2E1 inhibitors: may increase isoflurane concentrations - Halothane or other volatile anesthetics: additive CNS depression - Neuromuscular blocking agents: may potentiate blockade

Moderate Interactions (Monitor Closely): - Inhaled nitrous oxide: may affect minimum alveolar concentration (MAC) - Beta‑blockers: may enhance hypotensive effect - Diuretics: may exacerbate renal hypoperfusion